Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19
Status:
Completed
Trial end date:
2020-10-20
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, placebo-controlled, phase IIb clinical trial to assess
the efficacy of injectable methylprednisolone sodium succinate (MP) in patients with severe
acute respiratory syndrome (SARS) in COVID-19 infection. A total of 416 individuals of both
sexes, aged over 18 years old, with symptoms suggestive or confirmed diagnosis of severe
acute respiratory syndrome (SARS), hospitalized at the Hospital and Pronto-Socorro Delphina
Rinaldi Abdel Aziz (HPSDRAA), with clinical and radiological findings suggestive of SARS-CoV2
infection, will be randomized at a 1:1 ration to receive either MP (0.5mg/kg of weight, twice
daily, for 5 days) or placebo (saline solution, twice daily, for 5 days).
Phase:
Phase 2
Details
Lead Sponsor:
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado